CTAG2 and plasma cell myeloma: One study, in which TCRs are engineered to target a shared sequence between antigens New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and L-antigen family member 1 (LAGE-1), has reported an objective response rate of 80% at day 42 and median progression free survival of 13.5 months in 25 relapsed/refractory myeloma patients with at least one adverse cytogenetic abnormality (107).